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Epigenetic mechanisms may regulate the expression of 
pro-angiogenic genes, thus affecting reparative angiogen-
esis in ischemic limbs. The enhancer of zest homolog-2 
(EZH2) induces thtrimethylation of lysine 27 on histone 
H3 (H3K27me3), which represses gene transcription. We 
explored (i) if EZH2 expression is regulated by hypoxia and 
ischemia; (ii) the impact of EZH2 on the expression of two 
pro-angiogenic genes: eNOS and BDNF; (iii) the functional 
effect of EZH2 inhibition on cultured endothelial cells 
(ECs); (iv) the therapeutic potential of EZH2 inhibition in a 
mouse model of limb ischemia (LI). EZH2 expression was 
increased in cultured ECs exposed to hypoxia (control: 
normoxia) and in ECs extracted from mouse ischemic limb 
muscles (control: absence of ischemia). EZH2 increased 
the H3K27me3 abundance onto regulatory regions of 
eNOS and BDNF promoters. In vitro RNA silencing or phar-
macological inhibition by 3-deazaneplanocin (DZNep) of 
EZH2 increased eNOS and BDNF mRNA and protein lev-
els and enhanced functional capacities (migration, angio-
genesis) of ECs under either normoxia or hypoxia. In mice 
with experimentally induced LI, DZNep increased angio-
genesis in ischaemic muscles, the circulating levels of pro-
angiogenic hematopoietic cells and blood flow recovery. 
Targeting EZH2 for inhibition may open new therapeutic 
avenues for patients with limb ischemia.
Received 25 February 2014; accepted 23 August 2014; advance online  
publication 7 October 2014. doi:10.1038/mt.2014.163
INTRODUCTION
Chromatin regulation contributes to the modulation of endothe-
lial gene expression during vascular development and under dif-
ferent physiological and pathological conditions (reviewed in 1). 
Ischemic disease is a condition characterized by impaired blood 
perfusion. Therapeutic induction of the growth of new blood 
vessels is regarded as a possibility for improving the perfusion of 
ischemic tissue. Therefore, understanding the molecular mecha-
nism behind ischemia-initiated blood flow recovery is important. 
Surgical mouse models based on the obstruction of blood flow 
in the femoral, coronary or cerebral arteries, respectively lead-
ing to limb ischemia (LI), myocardial infarct or ischemic stroke, 
have significantly contributed to better understanding of the cel-
lular and molecular mechanisms behind postischemic revascu-
larization.2 In particular, the postischemic vascular regeneration 
requires establishment and regulations of angiogenic pathways, 
which act in concert to form a functional vascular network in the 
ischemic areas.3 Enhanced expression of angiogenic genes during 
hypoxia/ischemia is a primary requisite for vascularization and 
tissue regeneration (reviewed in 3). Evidence for a role of chro-
matin modifications in the regulation of the angiogenesis process 
are emerging4–6 and the epigenetic machinery behind endothelial 
gene expression and cell homeostasis during hypoxia/ischemia 
merits better understanding.7 N-terminal histone (H) tails are 
subject to posttranslational modification, including acetylation, 
methylation, phosphorylation, ubiquitination, and sumoylation.8 
Hypoxia-induced chromatin changes on gene expression could 
impact on clinical outcome in ischemic patients.3,9
In this study, we have focused on EZH2 methyltransferase 
(enhancer of zeste homolog-2), the catalytic component of the 
Polycomb Repressor Complex 2 (PRC2).10 EZH2 is the only enzyme 
capable to induce histone H3 bi (me2)- and tri (me3)- methyla-
tion of Lys 27 (H3K27me2 and H3K27me3) in mammalian cells.11 
Increased presence of H3K27me3 mark leads to transcriptional 
repression, whereas tri-methylation of H3 on lysine 4 (H3K4me3) 
positively associates with active transcription.12 Gene promoter 
regions commonly enriched for both H3K27me3 and H3K4me3 
are known as bivalent chromatin domains,12 which concur with the 
PRC2 occupancy.10,13 The interplay between H3K27/H3K4 trimethyl 
marks, and PRC2 recruitment, is of potential mechanistic signifi-
cance for re-activation of pro-angiogenic genes.14 Amongst several 
genes targeted by EZH2, in our study, we have focused at endothe-
lial nitric oxide synthase (eNOS/NOS3)14 and brain-derived neuro-
trophic factor (BDNF).15,16 eNOS is highly expressed in endothelial 
cells (EC), which have restricted potency and it defines their exclu-
sive endothelial identity through its promoter being stably integrated 
into the genome with a distinct chromatin signature.17 As a master 
regulator of endothelial function, eNOS is needed for endothelial 
homeostasis,18 and its activity is required for angiogenesis and blood 
flow recovery from limb ischemia.19 Moreover, eNOS in concert with 
Akt is part of the cell survival and pro-angiogenic pathways activated 
by several pro-angiogenic growth factors, including the BDNF.20,21 
BDNF is expressed persistently at high levels in adult ECs22 and 
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is known to promote vascular development and endothelial cell 
sprouting and to induce angiogenesis in vitro and in vivo in mice 
with LI.23–25 Our laboratory has a specific interest in the cardiovascu-
lar actions of neurotrophins and this additionally contributed to the 
selection of BDNF for this study. EZH2 requires noncatalytic protein 
subunits for its methylation activity: Suz12 (Suppressor of zeste-12 
homolog), EED (embryonic ectoderm development), and histone-
binding proteins RbAp48/46.10 Additionally, EZH2 reportedly regu-
lates gene expression in ECs26 and has been proposed to regulate the 
transcriptional program leading to endothelial lineage commitment 
of stem cells,14 cardiovascular developmental commitment27 and car-
diac homeostasis.28 Moreover, EZH2 is regulated by hypoxia in tumor 
microenvironment,29 where EZH2 appears to induce angiogenesis 
by a non-cell-autonomous mechanism.30 However, the role of EZH2 
in postischemic angiogenesis has not yet been investigated. Despite 
the individual evidence for eNOS and BDNF expression being under 
control of EZH214,16 and hypoxia,31,32 a link between EZH2 and 
hypoxia in regulating the expression of these two genes has not been 
previously established. Based on the information from the epigen-
etic silencing mechanisms, we reasoned that removal of H3K27me3 
using either EZH2 silencing or EZH2 pharmacological inhibition by 
3-deazaneplanocin (DZNep), an S-adenosylhomocysteine hydrolase 
inhibitor,33 could remodel chromatin surrounding these two genes 
which are important for endothelial function and repair, thus pro-
viding a setting in which the endothelial-genome is permissive to 
gene transcription and driving angiogenesis.
RESULTS
EZH2 inhibition increases the expression of eNOS and 
BDNF in HUVECs exposed to hypoxia
The EZH2 inhibitor DZNep has decreased levels of EZH2, 
H3K27me3, H3K27me2, and SUZ12 in HUVECs (Figure 1a) 
(Supplementary Figure S1i–iii). Similar results were obtained 
using small interfering RNA (siRNA)-mediated transient 
Figure 1 Hypoxia regulates PCR2, H3K27me3, eNOS, and BDNF levels and EZH2 inhibits eNOS and BDNF expression in HUVECs. (a) Western 
blot analyses of the PRC2 components EZH2 and SUZ12 and of the H3K27me3 and H3K27me2 epigenetic mark in HUVECs previously transfected 
with siRNA for EZH2, treated with the EZH2 inhibitor DZNep, or cultured in hypoxia (<2% O2) for 48 hours. Tubulin and histone H3 were used as 
housekeeping protein controls. Densitometry quantification of all Western blot analyses is presented in Supplementary Figure S1i–v. (b–d) mRNA 
expression levels of (b) EZH2 (c) eNOS, and (d) BDNF were measured in HUVECs using 18S as an internal control. Cells were transfected with EZH2 
siRNA or scramble (SCR) control and then cultured in normoxia (21% O2) or hypoxia (<2% O2) for 48 hours. (e–f) eNOS protein levels were detected 
using Western blot analysis to examine the effect of (e) EZH2 siRNA versus SCR or (f) DZNep versus Vehicle (V) on HUVECs under hypoxia against 
tubulin control. Densitometry quantification of Western blot analyses is presented in Supplementary Figure S2. (g–h) BDNF protein levels in 
HUVEC conditioned medium were detected using an ELISA to examine the effect of (g) EZH2 siRNA or (h) DZNep. All data were expressed as mean ± 
SEM. ##P < 0.01 and #P < 0.05 versus normoxia; **P < 0.01 versus hypoxia; +P < 0.0 versus siEZH2 in normoxia; ^P < 0.05 versus DZNep in normoxia; 
Experiments were performed in duplicate and repeated at least three times.
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knockdown of EZH2 (siEZH2) (Figure 1a) (Supplementary 
Figure S1ii–iv). Next, we studied the effect of hypoxia (<2% pO2 
for 48 hours) on H3K27me3, H3K27me2 levels and EZH2 expres-
sion in HUVECs. PCR primers for these analyzes are presented 
in Supplementary Table S1. Hypoxia increased the global lev-
els of H3K27me3 in HUVECs but not H3K27me2 (Figure 1a) 
(Supplementary Figure  S1v). As shown in Figure 1b, hypoxia 
also increased EZH2 mRNA levels in HUVECs (P < 0.01 ver-
sus normoxia) and as expected, siEZH2 reduced EZH2 under 
both normoxia and hypoxia (P < 0.01 for both comparisons). 
Moreover, hypoxia reduced eNOS (Figure 1c) and increased BDNF 
(Figure 1d) mRNA levels. PCR primers for these analyzes are pre-
sented in Supplementary Table S1. Next, we investigated if EZH2 is 
directly involved in the expressional regulation of eNOS and BDNF. 
siEZH2 maintained eNOS mRNA levels under hypoxia (Figure 1c), 
whereas DZNep was not tested in this experiment. Hypoxia reduced 
eNOS protein (Figure 1e–f) (Supplementary Figure S2i,ii) levels 
in HUVECs, with this effects being prevented by either siEZH2 
(Figure 1e) (Supplementary Figure S2i) or DZNep (Figure 1f) 
(Supplementary Figure S2ii). Hypoxia increased BDNF mRNA 
(Figure 1d) and protein (Figure  1g–h) levels. Moreover, EZH2 
inhibition by either siEZH2 (Figure 1g) or DZNep (Figure 1h) 
increased the release of BDNF by HUVECs under hypoxia.
PRC2 occupies the promoters of eNOS and BDNF
Taking advantage of the UCSC ENCODE Genome Browser 
(Human Feb. 2009, GRCh37/hg19),34 we analyzed chromatin 
marks at promoter region of two key endothelial-enriched genes 
using data generated by the ENCODE Consortium.35 Both eNOS 
and BDNF reportedly undergo transcriptional regulation by 
H3K27me3.16,36 Thus, we performed chromatin immunoprecipi-
tation using antibodies individually targeting PRC2 components 
(EZH2, SUZ12, and EED) and RNA polymerase II (RNA Pol II, 
which catalyses DNA transcription into mRNA). The character-
ization of eNOS and BDNF promoter region spanning around 
0.5 kb sequence upstream of transcription start site (TSS) was per-
formed using PCR primers for each of different promoter regions 
(Supplementary Table S2). Notably, RNA Pol II and PRC2 occupy 
gene promoters in a mutually exclusive manner.37 Indeed, our data 
show that displacement of PRC2 components from the promoter 
region of eNOS (Figure 2c) or BDNF (Figure 2d) was occurring 
together with the recruitment of RNA Pol II within TSS of each 
of the examined gene. At the same promoter regions, the histone 
mark of active gene transcription, H3K4me3 has previously been 
reported to be enriched and dominant at TSS.14 We subsequently 
observed enrichment of repressive mark H3K27me3, further 
upstream from the TSS, and it coincided with the PRC2 compo-
nents at the examined genes (Figure 2e,f).
Of note, using UCSC Genome Browser, we identified YY1 
putative DNA cis-element within the same region of eNOS 
(−121/−117 bp) and BDNF (−738/−733 bp) promoters, respectively. 
Presence of YY1 DNA cis-elements in the promoter has previously 
been suggested to participate in the formation of nucleoprotein 
complexes,38 thus further allowing recruitment of PRC2 at these 
sites.10 Interestingly, we observed an enrichment of YY1 protein 
(Supplementary Figure S3) in the same region of eNOS and BDNF 
promoters, respective with enrichment of EZH2 and H3K27me3.
Effect of hypoxia and DZNep on PRC2 and RNA 
polymerase II occupancy on eNOS and BDNF 
promoters in HUVECs
The PRC2 binding regions on eNOS (−493/−318 bp) and BDNF 
(−753/−480 bp) promoters were further investigated for the effect 
of hypoxia and DZNep on the binding of EZH2. Quantitative ChIP 
analysis showed an increased occupancy of the eNOS proximal 
promoter by EZH2 in HUVECs exposed to hypoxia and treated 
Figure 2 PCR2 binds to the eNOS and BDNF gene promoters, which are also exposed to histone 3 modifications. Binding of the PCR2 to the 
eNOS and BDNF gene promoters. Quantitative ChIP analysis of PRC2 complex proteins (EZH2, SUZ12, and EED) and RNA Pol II was performed in 
HUVECs to check their occupancy within 0.5 kbp locus on (a) eNOS (−496 to +7 bp from TSS, transcribed in [+] direction) and (b) BDNF (−814 to 
−7 bp from TSS, transcribed in [−] direction) within the promoter region. The binding of each PRC2 component and RNA polymerase are shown at 
the (c) eNOS and (d) BDNF gene promoters. IgG was used as a negative control. Data were calculated as % bound/input. All data were expressed 
as mean ± SD and are representative of at least n = 3 independently performed experiments.
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with the vehicle or DZNep (Figure 3a). Yet, hypoxia reduced the 
EZH2 occupancy of BDNF promoter (Figure 3c), corresponding 
to an increased BDNF gene expression. The enrichment profiles of 
EZH2 and H3K27me3 at the eNOS promoter were similar (Figure 
3a,b). Moreover, at the BDNF promoter, hypoxia induced a loss of 
both EZH2 and H3K27me3 in vehicle-treated HUVECs (Figure 
3c,d). Next, we investigated the occupancy of the eNOS and BDNF 
promoters by EZH2 and H3K27me3 in the presence of DZNep 
in normoxic and hypoxic HUVECs. As shown in Figure  3a–d, 
DZNep prompted loss of EZH2 and reduced H3K27me3 binding 
at both eNOS (Figure 3a,b) and BDNF (Figure 3c,d) promoters. 
Collectively, our results suggest the hypothesis that enrichment 
of EZH2 under hypoxia on the eNOS and BDNF promoters may 
modulate the transcriptional responses of endothelial genes to 
hypoxic environment.
EZH2 regulates functional responses of vascular 
endothelial cells to hypoxia
To reveal the functional role of EZH2 in endothelial cells, we 
investigated the effect of siEZH2 on HUVECs either cultured 
under normoxic condition or exposed to prolonged (48 hours) 
hypoxia. As shown in Figure 4a–c, hypoxia hampered the 
angiogenic capacity of HUVECs when tested by Matrigel assay. 
In fact, prolonged hypoxia has reduced both the endothelial 
cell tube-like length (Figure 4a) and the number of branching 
points (Figure 4b). Use of siEZH2 to knockdown EZH2 gene 
has improved HUVEC angiogenic potential under both nor-
moxia and hypoxia. Moreover, hypoxia decreased the migra-
tory capacity of HUVECs prompted in a scratch assay (Figure 
4d,e), whereas siEZH2 enhanced HUVEC migration under 
both normoxia and hypoxia. These results are in line with the 
increased expression of eNOS and BDNF in EZH2-silenced 
HUVEC (Figure 1c,d). The functional results of EZH2 knock-
down were corroborated by the use of pharmacological inhibitor 
of EZH2, DZNep. In fact, as shown in Supplementary Figure 
S4i–v, DZNep enhanced the HUVEC migratory and angiogenic 
potential under hypoxia.
To then validate the role of EZH2 in the observed pro-angio-
genic phenotype of HUVECs in Figure 4a,e and Supplementary 
Figure S4i–v, we performed a rescue experiment using adeno-
virus delivery of the wild type gene. Toward this end, we ini-
tially knocked down EZH2 in HUVEC, which again resulted in 
increased cell migration and network formation on Matrigel. We 
then performed a rescue experiment using adenovirus delivery 
of the wild type EZH2 cDNA (Supplementary Figure S5i–ii). 
We find that overexpression of the wild-type EZH2 adenovirus 
alone (SCR+AdwtEZH2) has reduced both the endothelial cell 
tube-like length (Supplementary Figure S6i) and the number 
of branching points (Supplementary Figure S6ii) when tested 
by Matrigel assay (Supplementary Figure S6iii), and fur-
ther reduced cell migration as compared with the Null control 
(SCR+AdNull), Supplementary Figure S6iv–v. Thus, reintro-
duction of a wild-type EZH2 adenovirus into pro-angiogenic 
siEZH2-transfected HUVECs (siEZH2+AdwtEZH2) has 
impaired their functional capacity by reducing cell ability to 
form network on Matrigel and cell migration (Supplementary 
Figure S6iii,v), as compared with the siEZH2 Null control 
(siEZH2+AdNull).
EZH2 inhibition by DZNep regulates eNOS and BDNF 
mRNA levels in endothelial cells of limb muscle
On the basis of our in vitro findings, we next asked if EZH2 is 
regulated by ischemia in vivo and if it modulates eNOS and BDNF 
expressional levels in the endothelial cells of limb muscles. To 
address these points, we used a mouse model of unilateral limb 
ischemia (LI). Mice were treated every 2 days with DZNep or 
vehicle control starting the day before induction of LI by left 
femoral artery occlusion and they were sacrificed at 2 and 7 days 
postsurgery. DZNep was well tolerated in these mice and we could 
not observe any weight loss or other gross side effects. DZNep 
reduced the levels of EZH2 protein (Figure 5a) and of H3K27me3 
and H3K27me2 (Figure 5b) in the ischemic limb muscles. In 
the vehicle group, ischemia increased EZH2 mRNA levels in the 
limb muscles (Figure 5c) and in muscular CD146pos endothelial 
cells (Figure 5d), prepared using a previously published proto-
col of ours.39 However, DZNep abolished these responses to isch-
emia (Figure 5c,d) and additionally reduced EZH2 mRNA levels. 
Figure 3 Effect of DZNep and hypoxia on EZH2 enrichment at eNOS 
and BDNF gene promoters. (a–d) Quantitative ChIP-PCR analyses of 
occupancy by (a,c) EZH2 and the (b,d) associated H3K27me3 modi-
fication of genomic regions (a,b) −493/−318 bp on eNOS and (c,d) 
−753/−480 bp on BDNF gene promoter in HUVECs. The promoter occu-
pancy was determined in the presence of DZNep or vehicle control (V) 
under normoxia and hypoxia and expressed as % chromatin bound/
input (for EZH2) or % total bound/H3 (for H3K27me3). 1% of total 
chromatin sample was used as input. IgG was used as a negative control. 
All data were expressed as mean ± SD and are representative of at least 
n = 3 independently performed experiments. #P < 0.05 versus vehicle 
under normoxia; *P < 0.05; **P < 0.01 versus vehicle under hypoxia.
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Moreover, as shown in Figure 5e, in the vehicle group, muscular 
eNOS mRNA expression was reduced at 7 days after LI induc-
tion. Notably, DZNep reversed this response to ischemia. In ECs 
extracted from either nonischemic muscles (from sham-operated 
mice) or muscles at 2 days after induction of ischemia in vivo 
DZNep resulted in increased eNOS mRNA levels (Figure 5f). 
Additionally, DZNep increased BDNF mRNA expression in the 
ischemic muscles (Figure 5g) and in the muscular CD146pos ECs 
(Figure 5h).
EZH2 inhibition by DZNep improves postischemic 
blood flow recovery and angiogenesis
Next, we asked if EZH2 inhibition by DZNep could improve 
blood flow recovery and angiogenesis after LI. Mice were injected 
with DZNep or vehicle (as described above) and the limb blood 
flow was monitored weekly before sacrificing mice at 21 days 
post-LI. DZNep was well tolerated for all this time and we could 
not observe further side effects. DZNep consistently improved the 
blood flow recovery (**P < 0.01 at day 7 and *P < 0.05 at days 14 
and 21 for comparisons versus vehicle) (Figure 6a). In addition, 
DZNep increased the density of both capillaries (Figure 6b–d) 
and small (<50 µmol/l diameter) arterioles (Figure 6c,d) in the 
ischemic adductor muscle at 3 weeks after LI (*P < 0.05 versus 
vehicle for both comparisons).
DZNep increases the abundance of circulating pro-
angiogenic cells in mice with limb ischemia
Bone marrow-derived pro-angiogenic cells contribute to post-
ischemic angiogenesis. eNOS allows for the egression of pro-
angiogenic cells from the bone marrow in response to an ischemic 
event.40 Moreover, BDNF reportedly promotes the liberation of 
hematopoietic Sca-1posCD11bpos cells in mice with LI.23 DZNep 
increased the circulating levels of pro-angiogenic Sca-1posCD11bpos 
cells (Figure 7a) and LinnegSca-1posc-kitpos (LSK) cells (Figure 7b) 
at 2 days after LI-induction (**P < 0.01 for both comparisons 
versus vehicle control). Supplementary Figure S7 shows the gat-
ing strategies for these flow cytometric analyses. Concomitantly, 
DZNep reduced the abundance of both Sca-1posCD11bpos cells 
(Figure 7c) and LSK cells (Figure 7d) in the bone marrow of isch-
emic mice. Taken together, our in vivo data are compatible with 
the hypothesis that EZH2 inhibition may act as an aiding tool to 
promote postischemic vascular regeneration by directly target-
ing the resident endothelial cells within the ischemic muscles 
and additionally stimulating the bone marrow to release pro- 
angiogenic cells into the systemic circulation.
DISCUSSION
Despite many exciting basic science discoveries, the field of 
therapeutic angiogenesis has not yet been able to translate the 
Figure 4 EZH2 inhibition increases the in vitro networking and migratory capacities of endothelial cells. (a–e) siRNA-mediated EZH2 knock-
down (control: scramble –SCR) was conducted in HUVECs to investigate the functional role of EZH2 using (a–c) Matrigel and (d,e) scratch assays. 
Functional property of HUVECs treated with DZNep or vehicle (V) control is presented in the Supplementary Figure S3i–iii. Cells were studied 
under (c) normoxia or hypoxia Matrigel and (e) scratch assay images and were taken at 5× magnification. Scale bar: 5 µm. For the Matrigel assay, 
(a) the average total length of tubes and (b) the total number of tubes branching points have been calculated. For the scratch assay, (d) the % gap 
closure was calculated. All measurements are mean ± SEM. #P < 0.05 versus SCR under normoxia; **P < 0.01 and *P < 0.05, versus SCR under hypoxia. 
Experiments were performed in triplicate and repeated at least three times.
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preclinical potential into clinical success (reviewed in 9,41). Loss 
of endothelial cell survival and function after injury impairs and 
delays the growth of blood vessels.41 In ischemic tissues, reduced 
blood perfusion and the low oxygen levels are unable to satisfy 
the metabolic needs.3 Fittingly, the importance of epigenetic 
mechanisms and hypoxia in endothelial gene regulation is gain-
ing more appreciation6,7 as our understanding of such mecha-
nisms is still in its infancy. The driving force in our research was 
the hope to develop a novel approach to stimulate postischemic 
angiogenesis productive for tissue reperfusion based on unlock-
ing the expression of pro-angiogenic genes, through modulation 
of the epigenetic landscape. In this study, we provide the first 
evidence that the histone H3 methyltransferase EZH2, the cata-
lytic subunit of the PRC2 complex, represses angiogenesis under 
hypoxia and ischemia. We found increased EZH2 in the endo-
thelial cells exposed to hypoxia. This is in line with the fact that 
EZH2 contains hypoxia response element (HRE).29 Moreover, 
we showed that in endothelial cells, hypoxia increases EZH2 to 
the regulatory regions of eNOS and BDNF gene promoters and 
augment the abundance of H3K27me3 at these locations, which 
perhaps results in chromatin condensation and gene silenc-
ing.10 Expression of eNOS was shown to decrease in hypoxia,31 
which is in line with our results. The hypoxia-induced increase 
in H3K27me3 on gene promoters (characteristic of a closed 
chromatin structure) can either counterbalance high levels of 
transcriptional activity (the case with eNOS in ECs) or poise 
active transcription at genomic regions (the case with BDNF 
under hypoxia).37 Accordingly, EZH2 depletion removed the 
repressive H3K27me3 epigenetic mark from both eNOS and 
BDNF gene promoters, hence increasing their expression in cul-
tured endothelial cells exposed to hypoxia. This correlated with 
improved functional capacities of endothelial cells. Moreover, 
Figure 5 Ischemia regulates the expression of EZH2, eNOS and BDNF in limb muscle and muscular ECs and DZNep increases eNOS and BDNF 
levels. Limb ischemia (LI) or sham operation was induced in mice. The ischemic limb adductor muscles were harvested from mice treated with 
DZNep or vehicle (V) and sacrificed at 3 days after surgery. Nonischemic muscle controls were taken from sham-operated mice. For protein analysis, 
total muscular nuclear fractions of protein were prepared and separated by Western blot to detect EZH2 protein levels against (a) Lamin A/C control 
or H3K27me3 and H3K27me2 levels against total histone H3. Densitometry quantification of Western blot analyses is presented in Supplementary 
Figure S1. (b) mRNA levels of (c,d) EZH2, (e,f) eNOS, and (g,h) BDNF were measured by qPCR using 18S as an internal control in the (c,e,g) total 
muscle or (d,f,h) muscular endothelial cells (CD146pos). Data are presented as mean ± SEM. #P < 0.05 versus vehicle in nonischemia; **P < 0.01 and 
*P < 0.05 versus vehicle in ischemia; +P < 0.05 versus DZNep in nonischemia; n = 5–8 mice/group.
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we have shown that the EZH2 inhibitor DZNep stimulates post-
ischemic blood flow recovery and reparative neovascularisation 
in the mouse LI model in vivo. It is conceivable that vascular 
endothelial cells can be epigenetically controlled to accelerate 
their pro-angiogenic capacity by modifying chromatin on the 
“key-regulatory” genes. Furthermore, our results emphasize two 
mechanistic features of PRC2, namely, its ability (i) to regulate 
eNOS and BDNF expression in human ECs and (ii) to add the 
H3K27me3 mark onto the promoter of these two genes under 
hypoxia. Our work fits with the hypothesis that under hypoxia 
increased or unchecked PRC2 activity affects the global and 
site-specific (on eNOS and BDNF promoter regions) level of 
H3K27me3 in endothelial cells and represses the transcription 
of eNOS and BDNF. In line with this hypothesis, ECs extracted 
from the ischemic limb muscles of mice treated with DZNep 
presented higher eNOS and BDNF mRNA levels. Thus, the 
resetting of epigenetic marks by inhibiting EZH2 in the endo-
thelial cells exposed to hypoxia could be consistent with gene 
transcriptional reactivation of additional angiogenic genes.
Using published UCSC Human Genome Browser resources,34 
we found that eNOS and BDNF gene promoter regions within 1 kb 
of TSS contain H3K27me3 mark. The eNOS promoter lacks a typi-
cal TATA box and it is not rich in CpG islands,17 yet the activa-
tion of the BDNF promoter is region-specific and it depends on 
the type of stimulus.42 There are YY1 DNA binding cis-element 
(5′-CCATT-3′, 5′-GCCAT-3′ or 5′-CGCCATNTT-3′) present 
within both of these gene promoters, which could participate 
in the binding of nucleoprotein complexes like PRC2 and con-
sequently trimethylate chromatin on H3K27.38 We observed an 
increased recruitment of PRC2 complex at YY1-regions in both 
eNOS and BDNF promoters. Whether YY1, through interaction 
with different transcription factors or with noncoding RNAs at 
its recognition sequences,38 could be involved in writing H3K27 
methylation11 under hypoxia it still remains to be investigated.
We have determined that in normoxia all three components 
of PRC2 bind chromatin of eNOS and BDNF promoters. While 
SUZ12 typically occupies genes that control transcription in 
development and differentiation,43 it is possible that it may 
assist eNOS and BDNF transcription along with EZH2, but its 
direct role was not studied in here, and preliminary work of ours 
shows loss of EC-function upon depletion of SUZ12 (data not 
shown). The RNA Pol II occupies genes controlling broader cell 
proliferation, and its activity on both eNOS and BDNF promot-
ers was prominent with the disappearance of PRC2 complex as 
already shown for pluripotency genes.37 Although we show that 
both genes are regulated by PRC2 enzymatic activity, additional 
layers of epigenetic regulation could be involved in determin-
ing deposition of H3K27me3 to directly influence eNOS and 
BDNF expression in ECs and under hypoxia. Moreover, angio-
genic responses under ischemia may require a reset of other 
epigenetic marks. For instance, the deposition of H3K27me2 
mark, could ensure structural function and contribute to the 
Figure 6 EZH2 inhibition improves postischemic blood flow recovery and angiogenesis in mice. (a–d) Unilateral limb ischemia was induced in 
mice (n = 12–16 mice/group), which were treated with either DZNep or vehicle (V) and studied for sequential blood flow recovery by (a) color laser 
Doppler before being sacrificed at 21 days postischemia for analyses of (b,d) capillary and (c,d) arteriole density in their ischemic muscles. Histology 
was performed in muscles from n = 7 mice/group (randomly selected from the mice undergoing the Doppler analyses). (a) Graph shows the time 
course of blood flow recovery to the ischemic foot. Pictures are representative of foot blood flow at 3 weeks postischemia, in a color scale with 
dark-blue being the lowest and dark-red the highest perfusion levels. (b) Capillary and (c) small arteriole densities are expressed per mm2 of muscle 
transverse section. (d) The representative immunofluorescent pictures were taken (at 20× magnification; size bar: 20 µm) after staining of ischemic 
adductor muscle sections with green fluorescent isolectin-B4 (revealing endothelial cells) and a red-fluorescence conjugated antibody targeting alpha 
smooth muscle actin (to identify smooth muscles cells which are present in arterioles, but not in capillaries). All data are mean ± SEM compared 
between DZNep treated and V control group. *P < 0.05 and **P < 0.01 versus V.
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activity of PRC2 to write H3K27me3.11 Deposition of regula-
tory permissive modifications like H3K36me3 along with the 
removal of EZH2/methylation of H3K27 at the poised genes, 
may be linked with higher mobility of histones and active gene 
transcription.11 It is yet unknown if demethylation of H3K27 
correlates with the increase in H3K36me3 or H3K27 acetyla-
tion at the selected genes during ischemia. It is also possible 
that the homolog of EZH2, EZH1, can contribute to writing 
trimethylation of H3K27.44 In fact, this may explain the differ-
ence observed in the levels of H3K27me3 at eNOS and BDNF 
promoters upon treatment of HUVEC with DZNep between 
normoxia and hypoxia. Additionally, the demethylase Jmjd3 
is suggested to be time-dependently increased by hypoxia and 
postinduction of limb ischemia in mice, whereby it contrib-
utes to the eNOS regulation.14 This is in line with the increased 
levels of H3K27me3 on eNOS promoter under hypoxia that 
could allow binding of Jmjd3. Since H3K27me3 is the only 
known substrate for Jmjd3, the latter enzyme could erase this 
repressive mark under hypoxia45 or ischemia, thus paving the 
way for the RNAPol II and active chromatin marks to fur-
ther direct endothelial gene expression. The accumulation of 
H3K27 methylation by PRC2 at the studied genes could also 
be a way of endothelial cell-type-specific maintenance of gene 
transcriptional repression. Thus, EZH2 inhibition may be one 
of the strategies for the reversal of chromatin changes in order 
to unlock endothelial cell angiogenic potential and to promote 
vascular regeneration in ischemic tissue.
Bone marrow mobilization of angiogenic progenitor cells is 
eNOS-dependent.40 In addition, eNOS levels regulate the post-
ischemic regenerative capacity of BM-derived progenitor cells.40 
Moreover, Kermani et al. showed that treatment with BDNF 
promotes the mobilization of pro-angiogenic hematopoietic Sca-
1posCD11bpos cells to the peripheral blood and it induces postisch-
emic recovery in mice with LI.23 Accordingly, we have shown that 
EZH2 inhibition by DZNep increases the circulatory levels of Sca-
1posCD11bpos and LSK cells after LI induction in mice. It is possible 
that EZH2 inhibition promotes angiogenesis by directly acting on 
differentiated endothelial cells, which are resident within the isch-
emic muscle and through promoting the liberation of BM cells, 
which have been shown to support angiogenesis, mainly through 
paracrine activities. In conclusion, EZH2 could represent a novel 
therapeutic target for preservation and restoration of function fol-
lowing limb ischemia, and the use of EZH2 inhibitors may be a 
tractable option for healing ischemic tissues.
Our in vivo data were produced in the young mice undergoing 
acute LI-induction, as such we could think of a clinical scenario 
with young patients who might have injured their limbs in acci-
dents, where these findings would be relevant. Further studies are 
necessary to investigate the clinical potential of EZH2 inhibition 
in the critical limb ischemia.
Finally, we cannot exclude the possibility that DZNep could 
induce angiogenesis in the nonischemic tissues. However, DZNep 
was shown to reduce cancer angiogenesis in mouse xenograft 
models, thus discouraging this hypothesis.30,46
Figure 7 EZH2 inhibition increased the abundance of circulating levels of hematopoietic pro-angiogenic cells in mice. (a–d) The abundance 
of hematopoietic (a,c) Sca-1posCD11bpos cells and (b,d) LinnegSca-1posc-kitpos cells in the (a,b) peripheral blood and (c,d) bone marrow was measured 
by flow cytometric analyses at 2 days after limb ischemia or sham-operation in mice treated with DZNep or vehicle control (V). Flow cytometry gat-
ing strategies are presented in Supplementary Figure S7. The number of cells in the blood and bone marrow was established using fluorescent 
counting beads. Data are presented as mean ± SEM, and compared with the relevant control. #P < 0.05 versus V in nonischemia, **P < 0.01 versus V 
in ischemia (LI); ++P < 0.01 and +P < 0.05 versus DZNep in nonischemia; n = 6–8 mice/group.
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MATERIALS AND METHODS
Cell culture and treatments. Human umbilical cord vein endothelial cells 
(HUVECs, Lonza, Slough, UK) were cultured at 37 °C with 5% CO2 in 
EBM-2 endothelial cell basal medium (Lonza) with addition of SingleQuot 
Kit (EGM-2 medium, Lonza) as instructed. For hypoxia experiments, cells 
were exposed to hypoxia (<2% pO2) for 48 hours (normoxia control: 21% 
pO2). The treatment with EZH2 inhibitor 3-deazaneplanocin, (DZNep, 
an S-adenosylhomocysteine hydrolase inhibitor, 2.5 µmol/l, CAS 102052-
95-9, Cayman; Cambridge Biosciences, Cambridge, UK) or DMSO con-
trol (0.2%, Sigma, Gillingham, UK) was performed in EGM-2 medium 
between 6 and 72 hours.
siRNA transfection and adenoviral transduction. For siRNA transfection, 
the cells were seeded on six-well plate at a density of 2 × 105 cells per well 
in 2 ml complete medium and grown for 1–3 days until 80% confluent. 
Lipofectamine 2000 (Life Technologies, Paisley, UK) was used to trans-
fect HUVECs and conduct siRNA-mediated transient knockdown of 
EZH2 (120 nmol/l flexitube siRNA, Qiagen, Manchester, UK). A scramble 
sequence (Qiagen) was used as control. For rescuing EZH2 expression, 
HUVECs were seeded on six-well plate at a density of 2 × 105 cells and 
grown until 80% confluent. Transduction was performed using adenovirus 
at concentration of 250 MOI, as previously described.47
Quantitative analysis of mRNA. Total RNA was isolated and reversely tran-
scribed using the Quantitect reverse-transcription kit (Qiagen) from cells 
or tissue. cDNA (equivalent to 300 ng total RNA) was incubated in tripli-
cate to assess gene mRNA expression of EZH2, eNOS and BDNF and 2 × 
ABI Power SYBR green mastermix (Life Technologies) PCR cycling and 
detection of fluorescent signal was carried out using a Roche Light Cycler 
480 (Roche, West Sussex, UK). Results were corrected for the expression of 
18S and expressed as the fold change. All primer sequences were obtained 
from PrimerBank, provided in Supplementary Table S1, and ordered from 
Quick Start (Sigma design).
Western blotting. Cells were treated with a lysis buffer (50 mmol/l Tris, 
pH 7.5, 150 mol/l NaCl, and 1 mol/l EDTA, 1% Triton X-100) contain-
ing 1 mmol/l sodium orthovanadate, 1 mmol/l sodium pyrophosphate, 1 
mmol/l sodium fluoride (all from Sigma) and mini-EDTA complete tab-
let (Roche). Lysates were prepared from frozen tissues by extraction into 
ice-cold lysis buffer (described above). Nuclear extracts were prepared 
using ice-cold S300 extraction buffer (9 mol/l urea, 25 mmol/l Tris-HCl 
pH6.8, 1 mmol/l EDTA, and 10% glycerol). The details of primary anti-
bodies used are provided in Supplementary Table S3 and they were used 
at following dilutions: EZH2 (clone RbAb AC22 1:1,000), pan H3 1:2,000 
(Active motif, La Hulpe, Belgium), SUZ12 1:2,000, EED 1:1,000 (Abcam, 
Cambridge, UK), H3K27me3, H3K27me2, H3K4me3, H3Ac (1:2,000 
Merck Millipore, Hertfordshire, UK), eNOS 1:2,000, β-actin 1:1,000 (Santa 
Cruz Biotechnology, Middlesex, UK), and BDNF (Promega, Southampton, 
UK; catalog number G164B). α/β-tubulin (2148S, 1:1,000) served as the 
loading control. Proteins were visualized with a goat anti-rabbit or donkey 
anti-goat secondary antibody (GE Healthcare, Little Chalfont, UK) and 
HRP substrate (Immobilon Western Chemiluminescent, Merck Millipore). 
We detected the chemiluminescent signal with X-ray film (GE Healthcare). 
The same membranes were usually stripped (with 20% Azide in 5% milk) 
and reused for detection of loading controls; band intensities were quanti-
fied using the densitometry and ImageJ analysis.
BDNF ELISA. An ELISA for (BDNF (Emax ImmunoAssay System, 
Promega) was carried out on HUVEC conditioned medium. Cells were 
either incubated with 2.5 µmol/l DZNep (control: vehicle, 0.2% DMSO) or 
have been previously transfected with siRNA-EZH2 (control: scramble). 
Cells were exposed to hypoxia (<2% pO2) for 48 hours (normoxia con-
trol: 21% pO2). The conditioned medium was collected from a confluent 
six-well plate (1 ml/well, 6 × 106 cells/well) and frozen at −80 °C until use, 
following manufacturer’s instructions.
In vitro angiogenesis and migration assay. HUVECs were transfected 
with siRNA for EZH2 or scramble control; or treated with DMSO versus 
DZNep (2.5 µmol/l), and seeded in 48-well plates coated with a growth fac-
tors-enriched Matrigel (BD Biosciences, Oxford, UK). Endothelial network 
formation was quantified in randomly captured microscopic fields (mag-
nification 5×) by calculating the length of cellular network. Cell migration 
was assayed by scratching the cell monolayer of confluent HUVECs. Cells 
were incubated with EGM-2 containing 2 mmol/l of hydroxyurea (Sigma) 
to arrest cell proliferation. Pictures were taken immediately after scratch-
ing 8 hours thereafter. The migration distance (in μm) as the reduction of 
the width of the open area was calculated.
Chromatin immunoprecipitation (ChIP). HUVECs (Lonza) were plated in 
T150 cm plates at a density of 2 × 106 cells per dish and treated with DMSO 
or DZNep (2.5 µmol/l) for 48 hours. Fully confluent cells were cross-
linked for 10 minutes with formaldehyde (1%) and quenched with glycine 
(0.125 mol/l) for further 5 minutes. Chromatin was sonicated (3 × 9 cycles 
30”ON/30”OFF) to an average of 300–500 bp DNA length using Bioruptor 
sonicator (Diagenode, Seraing, Belgium). ChIP assays were carried out as 
described before.43 Immunoprecipitation was performed in 1 ml volume 
with addition of 3–5 µg of the following antibodies; EZH2 (clone mAb 
AC22), pan H3 (Active motif), SUZ12, EED (Abcam), H3K27me3 (#07-
449), H3K27me2 (#07-452), H3K4me3 (#07-473), anti-H3KAc (#06-599) 
(Merck Millipore) or YY1 (sc-281), RNA Polymerase II (sc-889X) and IgG 
control (Santa Cruz Biotechnology). ChIP enriched DNA and input DNA 
was subjected to qRT-PCR analysis with ABI Power SYBR Green qPCR 
Master Mix (Life Technology) using specific primers sequence for eNOS 
and BDNF as reported (Supplementary Table S2). Enrichment by ChIP 
assay on the specific genomic regions was assessed relative to the input 
DNA and IgG control, or total histone H3. Within each ChIP experiment, 
a negative control ChIP was performed using 5 micrograms of polyclonal 
rabbit anti-mouse immunoglobulin (IgG). To verify the ChIP conditions, 
a qPCR was performed on enriched DNA using promoter primers against 
GAPDH for absence of histone modifications, or MYT-1 and Neurogenin 
D2 promoter region as known targets of polycomb group proteins. 
Associated DNA was then purified by extraction using QIA Quick qPCR 
kit (Qiagen). Quantitative PCR was used to determine recovery of specific 
DNA fragments. The promoter sequences for BDNF (Accession num-
ber 8188) and eNOS (Accession number 26552) were retrieved from the 
“Transcriptional Regulatory Element Database” website (http://rulai.cshl.
edu/cgi-bin/TRED/tred.cgi?process=home) and the transcription start sites 
were retrieved from the “DBTSS: Database of Transcriptional Start Sites” 
website (http://dbtss.hgc.jp/index.html?nmid=DBTSS:NM_000603) and 
the “Human (Homo sapiens) Genome Browser Gateway” website (http://
genome-euro.ucsc.edu/cgi-bin/hgGateway).
In vivo experiments. The experiments involving mice were covered by 
project and personal licenses issued by the United Kingdome Home Office 
and they were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals (the Institute of Laboratory Animal Resources, 
1996). CD1 male mice age 14 weeks were injected with DZNep (1.5 mg/
kg/day, i.p. every 2 days) or vehicle (1% DMSO in 0.9% saline) starting 1 
day before undergoing surgery to induce unilateral limb ischemia under 
general anesthetic, Avertin, after pre-operative analgesia (Vetergesic, 
0.05 ml/30 g animals). Limb ischemia was obtained by occlusion of the left 
femoral artery, as we reported previously.48 Sham-operated mice under-
went all surgical procedures apart from femoral artery occlusion. For 
mobilization and molecular biology analyses, mice were sacrificed at 2 or 
7 days after surgery, respectively. For the efficacy testing of DZNep, mice 
were studied for 3 weeks after surgery. The superficial blood flow to both 
feet was measured using high resolution laser color Doppler imaging sys-
tem (Moor LDI2, Moor Instruments, Devon, UK) at 30 minutes and days 
2, 7, 14, and 21 after limb ischemia. Blood flow recovery was calculated (n 
= 12–16 mice/group) as a ratio of ischemic over contralateral foot blood 
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flow. After the last Doppler analysis (at day 21 after surgery), mice were 
perfusion-fixed under terminal anesthesia and limb muscles were har-
vested for histological and immunohistochemical analyses.
Immunohistochemistry. Functional impact of DZNep treatment in 
CD1-ischemic mice was assessed by measuring capillary and arteri-
ole densities in the adductor muscle. Isolectin B4-FITC-conjugated 
bovine anti-sheep IgG (Life Technologies) was used to detect endothe-
lial cells, followed by staining with a red-conjugated rabbit polyclonal 
anti- α-smooth muscle actin (Sigma) used to stain smooth muscle cells 
(which are present in arterioles, but not in capillaries). Nuclei were 
stained with DAPI (4′,6-diamidino-2-phenylindole). The slides were 
mounted using a mounting medium (Vector Labs, Peterborough, UK). 
The relative amount of positive cells was counted in 10 randomly selected 
high-power fields (magnification 40×) using Zeiss inverted fluorescent 
microscope. Analyses were performed using muscles from eight mice per 
group and these mice were randomly selected from the ones used for 
laser color Doppler analyses.
Flow cytometry analyses. At three days from surgery to induce limb isch-
emia or sham-operation, blood and bone marrow cells were extracted from 
mice that have been treated with either DZNep or vehicle (as described 
above). Cells were stained with fluorescently labeled antibodies against 
cell lineages cocktails (Cat#55971), CD11b (clone M1/70; cat#55567), 
Sca1 (clone D7; cat#553108), and c-kit (clone 2B8; cat#553356) (all from 
BD Biosciences). Absolute count of cells per each sample was obtained 
using AccuCheck Flow Cytometry Counting Beads (Life Technologies). 
As shown in Supplementary Figure S7 (for peripheral blood), the major 
population of lympho-mononuclear cells was resolved on a dot plot of 
linear forward light scatter (FSC) versus linear side light scatter (SSC) and 
it was gated into a region P1 to exclude contaminating events such as red 
blood cells, platelets, and cell debris. The cell populations were analyzed 
on a double-laser BD FACSCANTO system (BD Biosciences). For detect-
ing CD11posSca-1pos cells, the Sca-1 events were established on a dot plot of 
Sca-1 staining versus FSC and they were gated into a region designated P3, 
where they were analyzed for CD11b staining, with CD11bpos cells being 
gated into a region designated P4. For detecting linnegSca-1posc-kitpos cells, 
lineage negative events were established on a dot plot of lineage negative 
staining versus FSC, and were gated into a region designated P3, where 
they were analyzed for Sca-1 and c-kit staining, with CD11bposc-kitpos cells 
being gated into a region designated P4. An equivalent approach was used 
for bone marrow analyses.
CD146pos cell isolation from mouse limb muscles. Adductor muscles were 
collected at 2 days after surgery from mice previously treated with DZNep 
or vehicle as reported above. Muscles were rinsed in PBS and digested 
with collagenase II (600 U/ml final, Worthington) and DNase I (1 mg/
ml, Sigma) using gentle MACS dissociator (Miltenyi Biotech, Surrey, UK) 
M tubes (130-093-236) and following the manufacturer’s protocol. Next, 
endothelial cells were sorted using an immunomagnetic CD146 antibody 
(clone ME-9F1, Miltenyi Biotech), as previously reported.39
Computer analysis. Genome-wide searching approaches have been used 
to predict the importance of the PRC2 complex in the regulation of tran-
scription of endothelial targets through H3K27 methylation. To identify 
the family or individual transcription factors that potentially bind to the 
identified sequences, genomic regions from UCSC ENCODE genome 
browser34,49 were compared against a comprehensive library of known 
motifs consisting of motif matrices from the JASPAR database (http://jas-
par.genereg.net/).50 The motifs derived from published transcription factor 
ChIP-seq data were compared against the motifs that are not represented 
in the known UCSC genomic sequence of genes of interest. Further analy-
sis of characterized Polycomb/Trithorax Response Elements (PRE/TREs 
or PREs for short) was performed using jPREdictor tool http://bibiserv.
techfak.uni-bielefeld.de/jpredictor.
Statistical analysis. Data are expressed as means ± SEM. Data were ana-
lyzed using GraphPad Prism (version 5; GraphPad Software, San Diego, 
CA). Two-group comparisons were performed with Student t test with P ≤ 
0.05 taken as statistically significant. Multi-group analysis was performed 
using two-way analysis of variance to compare the combined and indi-
vidual effect of ischemia and DZNep treatment, or combined individual 
effect of hypoxia and siEZH2. Statistical significance was determined at a 
value of P ≤ 0.05 with Bonferroni posttest.
SUPPLEMENTARY MATERIAL
Figure S1. Quantification of Western blot analyses presented in the 
Figure 1a.
Figure S2. Quantification of Western blot analyses presented in the 
Figure 1e.
Figure S3. Binding of YY-1 to the eNOS and BDNF gene promoters.
Figure S4. DZNep increases the in vitro networking and migratory 
capacities of endothelial cells.
Figure S5. Overexpression of wild type EZH2 into HUVECs and quan-
tification of Western blot analyses.
Figure S6. Rescuing the EZH2 protein levels in HUVECs worsens the 
endothelial cell function.
Figure S7. Flow cytometry strategies behind the data presented in 
the Figure 7a,b.
Table S1. Sequence of qPCR primers used in this study.
Table S2. Sequence of primer used for chromatin immunoprecipita-
tion (ChIP) qPCR analysis in this study.
Table S3. The list of antibodies used in the study.
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